InvestorsHub Logo
Followers 47
Posts 18364
Boards Moderated 0
Alias Born 02/26/2001

Re: IB_ post# 276775

Friday, 11/10/2017 12:24:37 AM

Friday, November 10, 2017 12:24:37 AM

Post# of 404687
Like I SAID RIGHT AGAIN! ANOTHER CRL for NORCO! BINGO! I predictd that how long ago. I don't see approval coming for PERCOCET EITHER for BOTH of these.
Market is already flooded with this POISON!

NasRAT can't even file GENERICS hysterically FUNNY!

The Company received a CRL from the FDA in October 2017 regarding the ANDA filing and intends to submit a response to the FDA to address deficiencies listed. Please note that there can be no assurances of this product receiving marketing authorization, or achieving commercialization. In addition, even if marketing authorization is received and the product is commercialized, there can be no assurances of future revenues or profits in such amounts that would provide adequate return on the significant investments made to secure marketing authorization for this product.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News